Abstract:Rare eye diseases encompass a broad spectrum of genetic anomalies with or without additional extraocular manifestations. Genetic eye disorders in pediatric patients often lead to severe visual impairments. Therefore, a challenge of gene therapy is to provide better vision to these affected children. In recent years, inherited retinal diseases, inherited optic neuropathies, and corneal dystrophies have dominated discussions to establish gene and cell replacement therapies for these diseases. Gene therapy involves the transfer of genetic material to remove, replace, repair, or introduce a gene, or to overexpress a protein, whose activity would have a therapeutic impact. For the majority of anterior segment diseases, these studies are still emerging at a preclinical stage; however, for inherited retinal disorders, translation has been reached, leading to the introduction of the first gene therapies into clinical practice. In the past decade, the first gene therapy for biallelic RPE65-mediated inherited retinal dystrophy has been developed and the FDA and EMA both approved ocular gene therapy. Other promising approaches by intravitreal injection have been investigated such as in CEP290-Leber congenital amaurosis. Various techniques of gene therapies include gene supplementation, CRISPR-based genome editing, as well as RNA modulation and optogenetics. Optogenetic therapies deliver light-activated ion channels to surviving retinal cell types in order to restore photosensitivity. Beyond retinal function, ataluren, a nonsense mutation suppression therapy, enables ribosomal read-through of mRNA containing premature termination codons, resulting in the production of a full-length protein. An ophthalmic formulation was recently evaluated with the aim of repairing corneal damage, pending new clinical studies. However, various congenital disorders exhibit severe developmental defects or cell loss at birth, limiting the potential for viral gene therapy. Therefore mutation-independent strategies seem promising for maintaining the survival of photoreceptors or for restoring visual function. Restoring vision in children with gene therapy continues to be a challenge in ophthalmology. © 2023 Published by Elsevier Masson SAS on behalf of French Society of Pediatrics.

Advances in Gene Therapy for Diseases of the Eye

Update on gene therapies in pediatric ophthalmology

Genetic engineering and the eye

Use of gene therapy for optic nerve protection: Current concepts

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology

Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: progress towards non-viral systems

Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review

Gene editing technology: Towards precision medicine in inherited retinal diseases

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

AAV for Gene Therapy in Ocular Diseases: Progress and Prospects

Ocular Gene Therapy: Literature Review

Advances in Ophthalmic Optogenetics: Approaches and Applications

Gene and cell-based therapies for retinal and optic nerve disease

Advances in gene therapy for glaucoma

Progress and Prospects of Gene Therapy in Ophthalmology from 2000 to 2022: A Bibliometric Analysis

Update on Viral Gene Therapy Clinical Trials for Retinal Diseases

Gene therapy for glaucoma: Targeting key mechanisms

Genes as drugs for glaucoma: latest advances

Genome editing in the treatment of ocular diseases

A Mini-Review on Gene Therapy in Glaucoma and Future Directions

Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing